Edesa Biotech is trading 10.28% up now at $5.90 in after-hours trading after closing at $5.35 on August 14, 2026, as the clinical milestone appears to outweigh earnings and liquidity concerns.
- August 13 third-quarter results showed a $5.4 million net loss and sharply higher research spending.
- Management confirmed Phase 2 EB06 vitiligo-site activation and expected recruitment in the coming weeks.
- No separate August 14 company announcement was identified.